血清乳酸脱氢酶水平与初诊老年多发性骨髓瘤病人预后的相关性分析

doi:10.3969/j.issn.1003-9198.2021.01.010

Abstract

Abstract: Objective To investigate the correlation between serum lactate dehydrogenase (LDH) and the clinical indicators in the elderly patients with newly diagnosed multiple myeloma (MM) and its prognostic significance. Methods The clinical data of 78 cases of newly diagnosed MM aged ≥65 years old in our hospital from July 2009 to January 2016 were analyzed retrospectively. The relationship between serum LDH level and prognosis was analyzed by Kaplan-Meier survival curve. The revised International Staging System (R-ISS) staging of 60 MM patients with complete data was carried out based on the patient's LDH level and fluorescence in situ hybridization test result, and the accuracy of prognostic judgment was compared with the International Staging System (ISS) staging. Results The median follow-up time for all the patients was 16. 5 months, and 11. 5% (9/78) of the patients showed elevated LDH levels at the first visit. The median survival time (OS) of the normal LDH group was 44. 0 months, compared with 14. 0 months of the elevated LDH group (P<0. 001); The median progression-free survival time (PFS) of the normal LDH group was 23. 0 months, compared with 12. 0 months of the elevated LDH group (P=0. 006). COX multivariate regression analysis showed that elevated LDH level was an independent poor prognostic factor for OS in the elderly MM patients (HR=5. 998, 95%CI: 2. 454-14. 664, P<0. 001). There were no significant differences in median OS and median PFS between stage Ⅱ and Ⅲ of ISS (44. 0 months vs 39. 0 months, P=0. 713; 26. 0 months vs 20. 0 months, P=0. 569), while there was significant difference in median OS (44. 0 months vs 15. 5 months, P<0. 001), and no significant difference in median PFS (21. 0 months vs 14. 0 months, P=0. 097) between stage Ⅱ and Ⅲ of R-ISS. Conclusions LDH level is an important indicator for judging the prognosis of the elderly MM patients. R-ISS staging based on LDH level is superior to ISS staging in predicting prognosis.

Key words: lactate dehydrogenase, multiple myeloma, revised international staging system, prognosis analysis

CLC Number:

R 733.3

CHEN Hao-yu, LU Xiu-pan, CHEN Li-juan, XU Ji. Correlation analysis between serum lactate dehydrogenase and prognosis in elderly patients with newly diagnosed multiple myeloma[J]. Practical Geriatrics, 2021, 35(1): 36-40.

References

[1] TERPOS E, KATODRITOU E, ROUSSOU M, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents[J]. Eur J Haematol, 2010, 85(2):114-119.
[2] BARLOGIE B, BOLEJACK V, SCHELL N, et al. Prognostic factor analyses for multiple myeloma survival with intergroup trial S9321(INT0141): examining whether different variable govern different time segments of survival[J]. Ann Hematol, 2011, 90(4):423- 428.
[3] 李红梅, 侯健, 戚春建, 等. 多发性骨髓瘤患者血清乳酸脱氢酶水平与病程及预后关系的分析[J]. 中华血液学杂, 2004, 25(10):52-53.
[4] GREIPP P R, SAN MIGUEL J, DURIE B G, et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005, 23(15):3412-3420.
[5] DURIE B G, SALMON S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival[J]. Cancer, 1975, 36(3):842-854.
[6] CHANG H, QI X, JIANG A, et al. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma[J]. Bone Marrow Transplant, 2010, 45(1):117-121.
[7] XIONG W, WU X, STARNES S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma[J]. Blood, 2008, 112(10):4235-4246.
[8] ROSS F M, AVET-LOISEAU H, AMEYE G, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders[J]. Haematologica, 2012, 97(8):1272-1277.
[9] GAO X, LI C, ZHANG R, et al. Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma[J]. Med Oncol, 2012, 29(3):2200-2206.
[10] PALUMBO A, AVET-LOISEAU H, OLIVA S, et al. Revised international staging system for multiple myeloma: A Report From International Myeloma Working Group [J]. J Clin Oncol, 2015, 33(26):2863-2869.

Correlation analysis between serum lactate dehydrogenase and prognosis in elderly patients with newly diagnosed multiple myeloma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Metrics

Recommended 10

[1]	JIN Ling, ZHOU Zhi-gang. Study on lymphocyte-to-monocyte ratio in evaluating prognosis of multiple myeloma in elderly patients [J]. Practical Geriatrics, 2021, 35(6): 580-583.
[2]	CHU Hong, CHEN Yan, YING Xiu-hua, WANG Qian, HUANG Ting. The status of self-perceived burden in elderly inpatients with multiple myeloma and its influencing factors [J]. Practical Geriatrics, 2021, 35(10): 1087-1091.